Adjuvants and inactivated polio vaccine: A systematic review

Vaccine

Volumn 30, Issue 49, 2012, Pages 6971-6979

  Hawken, Jennifer ^a   Troy, Stephanie B ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Immunogenicity; Inactivated polio vaccine (IPV)

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM OXIDE; ALUMINUM PHOSPHATE; CALCIUM PHOSPHATE; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; FREUND ADJUVANT; HOLMIUM; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; MINERAL OIL; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VITAMIN D;

ANTIBODY TITER; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; EMULSION; ERYTHEMA; FLU LIKE SYNDROME; GRANULOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; LIMB PAIN; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SKIN INDURATION; SWELLING; SYSTEMATIC REVIEW; VACCINATION; VITAMIN D DEFICIENCY;

ADJUVANTS, IMMUNOLOGIC; DISEASE ERADICATION; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED;

EID: 84869095707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.059     Document Type: Review

References (53)

1. Data and monitoring polio this week; 2012. Available from: [accessed 01.07.12]. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
2. Zehrung D, Hickling J, Jones R, Nundi N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: an economic analysis of strategies to reduce the cost of routine IPV immunization; 2010. Available from: [accessed 01.07.12]. http://www.path.org/publications/details.php?i=1809.
3. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010, 85:213-228.
4. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010, 1213-1229.
5. Minor P.D., Macadam A.J., Stone D.M., Almond J.W. Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 1993, 357-363.
6. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006, 117-122.
7. Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Mwanza M., Corander J., et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010, 2360-2369.
8. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 2012, 121-125.
9. Nirmal S., Cherian T., Samuel B.U., Rajasingh J., Raghupathy P., John T.J. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998, 16(May-June (9-10)):928-931.
10. Dekker C., Gordon L., Klein J. Dose optimization strategies for vaccines: the role of adjuvants and new technologies 2008, HHS: NVAC Subcommittee on Vaccine Development and Supply, Washington, DC.
11. Plotkin S., Vidor E. Poliovirus vaccine - inactivated. Vaccines 2008, 605-630. Saunders/Elsevier, Philadelphia. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
12. Sutter R. Poliovirus vaccine - live. Vaccines 2008, 631-686. Saunders/Elsevier, Philadelphia. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
13. Vogel F., Hem S. Immunologic adjuvants. Vaccines 2008, 59-71. Saunders/Elsevier, Philadelphia. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
14. Picciotto L., Brancato P. Serological response of guinea pigs to inoculation with anti-poliomyelitis vaccine containing adjuvant substances. Riv Ist Sieroter Ital 1960, 35(January-February):70-76.
15. Auerswald W., Juergenssen O. On the problem of antibody formation against poliomyelitis in small children. Studies on the effect of an adjuvant vaccine with antigen components against poliomyelitis, diphtheria, pertussis and tetanus. Wien Med Wochenschr 1960, 110(August):646-648.
16. Henneberg G., Drescher J., Godglueck G., Gruetzner L. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta. Am J Hyg 1962, 75(January):44-55.
17. Drescher J., Grutzner L., Godgluck G. Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta. Am J Epidemiol 1967, 85(May (3)):413-423.
18. Emini E.A., Schleif W.A., Jameson B.A., Wimmer E. The immune response to poliovirus specific synthetic peptides: effects of adjuvants and test animal species. J Virol Methods 1985, 10(February (2)):163-170.
19. Yeh S.H., Ward J.I., Partridge S., Marcy S.M., Lee H., Jing J., et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr Infect Dis J 2001, 20(October (10)):973-980.
20. Li R.C., Li F.X., Li Y.P., Hou Q.M., Li C.G., Li Y.N., et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 2011, 29(February (10)):1913-1920.
21. Guerra F.A., Blatter M.M., Greenberg D.P., Pichichero M., Noriega F.R. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009, 123(January (1)):301-312. Pentacel Study Group.
22. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 155-172.
23. Relyveld E.H. Preparation and use of calcium phosphate-adsorbed vaccines. Dev Biol Stand 1986, 65:131-136.
24. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 1994, 22(March (1)):53-63.
25. He Q., Mitchell A.R., Johnson S.L., Wagner-Bartak C., Morcol T., Bell S.J. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 2000, 7(November (6)):899-903.
26. Sureau P., Fabre P.S., N'Garo S.B., Butor S.C., Poulougou M.M., Relyveld E.H. Simultaneous tetanus and poliomyelitis vaccination of infants in a tropical environment. Bull World Health Organ 1977, 55(6):739-746.
27. Kravchenko A.T., Tsetlin E.M., Omel'chenko T.N. Rational method of producing sera with high titers of virus neutralizing antibodies. Zh Mikrobiol Epidemiol Immunobiol 1977, (1):41-45.
28. Ward R., Rader D., Lipton M.M., Freund J. Formation of neutralizing antibody in monkeys injected with poliomyelitis virus and adjuvants. Proc Soc Exp Biol Med 1950, 74(July (3)):536-539.
29. Salk J.E., Lewis L.J., Youngner J.S., Bennett B.L. The use of adjuvants to facilitate studies on the immunologic classification of poliomyelitis viruses. Am J Hyg 1951, 54(September (2)):157-173.
30. Hilleman M.R., Hampil B., Sweet B.H. Poliovirus vaccines in mineral oil adjuvant. I. Animal toxicity and serologic response data. J Allergy 1963, 34(September-October):413-419.
31. Stone S., Hu R., Krugman S., Tytell A.A., Hilleman M.R. Poliovirus vaccines in mineral oil adjuvant. II. Clinical reaction and antibody response. J Allergy 1963, 34(September-October):420-425.
32. Cutler J.C., Lesesne L., Vaughn I. Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered. J Allergy 1962, 33(May-June):193-209.
33. Baldwin S.L., Fox C.B., Pallansch M.A., Coler R.N., Reed S.G., Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011, 29(January (4)):644-649.
34. Durando P., Icardi G., Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010, 10(April (4)):639-651.
35. Nishimura K., Nishimura S., Nishi N., Saiki I., Tokura S., Azuma I. Immunological activity of chitin and its derivatives. Vaccine 1984, 2(March (1)):93-99.
36. Ghendon Y., Markushin S., Krivtsov G., Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 2008, 153(5):831-837.
37. Ghendon Y., Markushin S., Akopova I., Koptiaeva I., Krivstov G. Chitosan as an adjuvant for poliovaccine. J Med Virol 2011, 83:847-852.
38. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55.
39. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010, 56(April (3)):290-299.
40. Kim J.K., Han K.H., Lee J.T., Paik Y.H., Ahn S.H., Lee J.D., et al. Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res 2006, 12(January (2)):543-548.
41. Lemire J.M. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem 1992, 49(May (1)):26-31.
42. Kriesel J.D., Spruance J. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine 1999, 17(April (15-16)):1883-1888.
43. Ivanov A.P., Dragunsky E.M., Chumakov K.M. 1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006, 193(February (4)):598-600.
44. Hackman K.L., Gagnon C., Briscoe R.K., Lam S., Anpalahan M., Ebeling P.R. Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust 2010, 192(June (12)):686-689.
45. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374(April (6522)):546-549.
46. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(April (4)):499-511.
47. Yang C., Shi H., Zhou J., Liang Y., Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009, 27(November (47)):6558-6563.
48. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000, 164(January (2)):944-953.
49. Sogaard O.S., Lohse N., Harboe Z.B., Offersen R., Bukh A.R., Davis H.L., et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51(July (1)):42-50.
50. Vogel F.R., Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995, 6:141-228.
51. Landi S., Penney C.L., Shah P., Hart F., Campbell J.B., Cucakovich N. Adjuvanticity of stearyl tyrosine on inactivated poliovirus vaccine. Vaccine 1986, 4(June (2)):99-104.
52. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 2256-2272.
53. Tan L., Weissig V., Gregoriadis G. Comparison of the immune response against polio peptides covalently-surface-linked to and internally-entrapped in liposomes. Asian Pac J Allergy Immunol 1991, 9(June (1)):25-30.